
The fund aims to achieve substantial long-term capital growth. It accomplishes this through a dynamic allocation strategy across global equity markets, informed by the investment team's ongoing assessment of the macroeconomic environment and prevailing market conditions. The approach combines focused, actively managed positions in both U.S. and international stocks with the broad diversification provided by index-tracking exchange-traded funds. Portfolio components are constructed using index-based ETFs targeting specific U.S. sectors and international regions, carefully chosen to balance desired market exposures against their associated costs and risks.
Is GLOW's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p

Toronto, Ontario--(Newsfile Corp. - June 13, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that it has granted 3,050,000 stock options (the "Options") to various directors, officers, employees and consultants of the Company. Each Option is exercisable at a price of $0.06 for one common share of the Company (each a "Common Share") for a period of five years from the date of grant and are being issued under the terms of the Company's Omnibus Long-Term Incentive Plan.

Toronto, Ontario--(Newsfile Corp. - June 2, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the first quarter ended March 31, 2025 ("Q1 2025). In Q1 2025, Glow delivered record revenue, sustained high gross margins, and achieved key balance sheet improvements, reflecting the Company's continued focus on delivering sustainable, profitable growth.

Toronto, Ontario--(Newsfile Corp. - May 1, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the fourth quarter and the fiscal year ended December 31, 2024 ("Q4 2024" and "FY 2024"). In Q4 2024, Glow achieved record revenue, industry-leading gross margins, and key balance sheet improvements, reflecting the Company's commitment to delivering sustainable, profitable growth.

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significance PALO ALTO, Calif.